Tecan Group
SWX:TECN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
WA
Consensus Narrative from 8 Analysts
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
Key Takeaways Expansion into South Korea and FDA approval in Malaysia bolster Tecan's production and revenue growth potential in medical devices. Innovations in genomics and proteomics could drive demand and revenue as new technologies gain market traction.
View narrativeCHF 250.50
FV
29.4% undervalued intrinsic discount6.44%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 days ago author updated this narrative